If you have symptoms of fever, cough or difficulty breathing, have traveled to areas impacted by the Coronavirus (2019-nCoV) within the past 14 days, and/or have been in close contact with someone who has traveled outside the US or been exposed to the Coronavirus please call your primary clinic before coming in for your appointment. We have also made temporary changes to who may accompany patients to appointments and treatments. Learn More

Research Institute

Available Trials

A randomized, multicenter, double blind Phase 3 study of PD-0332991 (Oral CDK 4/6 inhibitor) plus letrozole versus placebo plus letrozole for the treatment of postmenopausal women with ER(+), HER2(-) breast cancer who have not received any prior systemic anti-cancer treatment for advanced disease.

 

Bladder

Breast

Colon

Gastrointestinal

  • Phase 3 Study of INCMGA00012 in Anal Cancer

    A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy


  • Phase 3 Study of Sintilimab in Esophageal Cancer

    A Multicenter, Double-Blind, Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo, in Combination with Chemotherapy, for First-Line Treatment of Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma


  • Phase 3 Study of Infigratinib vs. Gemcitabine with Cisplatin in Cholangiocarcinoma

    A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations


  • Phase 3 Study of Pembrolizumab in 1st Line Biliary Tract Carcinoma

    A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine/Cisplatin versus Placebo Plus Gemcitabine/Cisplatin as First-Line Therapy in Participants with Advanced and/or Unresectable Biliary Tract Carcinoma


  • Chemotherapy +/- Pembrolizumab in 1st Line Her2- Gastric or GEJ cancer

    A Phase 3, randomized, double-blind clinical study of pembrolizumab (MK-3475) plus chemotherapy versus placebo plus chemotherapy as first-line treatment in participants with HER2 negative, previously untreated, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma


  • Trastuzumab/Chemotherapy +/- Pembrolizumab in 1st Line Her2+ Gastric or GEJ Cancer

    A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab Plus Chemotherapy and Placebo as First-line Treatment in Participants With HER2 Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma


Head and Neck

Hematology

  • Phase 3 Study of Navitoclax in Myelofibrosis

    A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Navitoclax in Combination with Ruxolitinib versus Ruxolitinib in Subjects with Myelofibrosis


  • Phase 3 Study of Pacritinib in Severe Thrombocytopenia

    A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia


Hepatic

Leukemia

Lung

Lymphoma

Melanoma

Myelomas

Ovarian

Pancreatic

Prostate

Renal

Solid Tumors